Health-care companies fell as traders rotated out of defensive sectors back into the high-risk tech sector.
Novo Nordisk shares slipped after analysts at brokerage Deutsche Bank cut their rating on the Ozempic maker, warning that a recent deceleration in sales growth could continue. Intensified competition from Eli Lilly and smaller rivals has weighed on the Danish giant's earnings in recent quarters, as it gives up some of its early lead on the wildly popular GLP-1 category of drugs.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments